Nicolas Meyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9345460/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. New England Journal of Medicine, 2015, 372, 2006-2017.	27.0	2,489
2	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2016, 17, 1558-1568.	10.7	827
3	TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nature Communications, 2017, 8, 2256.	12.8	284
4	Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. European Journal of Cancer, 2017, 86, 334-348.	2.8	212
5	Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncology, The, 2015, 16, 729-736.	10.7	198
6	The TNF Paradox in Cancer Progression and Immunotherapy. Frontiers in Immunology, 2019, 10, 1818.	4.8	198
7	Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2015, 72, 992-1002.	1.2	162
8	Psoriasis: an epidemiological evaluation of disease burden in 590 patients. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1075-1082.	2.4	87
9	Geoepidemiologic considerations of auto-immune pemphigus. Autoimmunity Reviews, 2010, 9, A379-A382.	5.8	82
10	Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clinical Cancer Research, 2021, 27, 1037-1047.	7.0	55
11	Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma. Journal of Oncology, 2018, 2018, 1-9.	1.3	53
12	Pruritus in Cutaneous T-cell Lymphomas: Frequent, Often Severe and Difficult to Treat. Acta Dermato-Venereologica, 2010, 90, 12-17.	1.3	51
13	Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients. Journal of Clinical Oncology, 2019, 37, 3275-3282.	1.6	41
14	Highâ€frequency ultrasonography but not 930â€nm optical coherence tomography reliably evaluates melanoma thickness <i>in vivo</i> : a prospective validation study. British Journal of Dermatology, 2014, 171, 799-805.	1.5	39
15	RhoB Promotes Cancer Initiation by Protecting Keratinocytes from UVB-Induced Apoptosis but Limits Tumor Aggressiveness. Journal of Investigative Dermatology, 2014, 134, 203-212.	0.7	28
16	Awareness, knowledge and attitudes towards sun protection among skin cancer-treated patients in France. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 070209222700006-???.	2.4	27
17	Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient's satisfaction and reduces the need for surgical procedures. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 864	2.4	25
18	Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. British Journal of Dermatology, 2018, 178, 1199-1203.	1.5	25

NICOLAS MEYER

#	Article	IF	CITATIONS
19	Vemurafenib significantly decreases glomerular filtration rate. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 978-979.	2.4	24
20	Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy. British Journal of Cancer, 2018, 119, 193-199.	6.4	21
21	Anti-TNF, a magic bullet in cancer immunotherapy?. , 2019, 7, 303.		21
22	Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximabÂand radiotherapy. European Journal of Cancer, 2018, 90, 142-145.	2.8	19
23	Cutaneous T Cell Lymphoma Complicating Severe Atopic Dermatitis. Dermatology, 2009, 218, 168-171.	2.1	16
24	Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e73-e74.	2.4	15
25	Sentinel lymph node biopsy for melanoma is becoming a consensus: a national survey of French centres involved in melanoma care in 2008. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1230-1235.	2.4	14
26	Factors associated with sun protection compliance: results from a nationwide cross-sectional evaluation of 2215 patients from a dermatological consultation. British Journal of Dermatology, 2014, 170, 1327-1335.	1.5	14
27	Enzalutamide induced acute generalized exanthematous pustulosis. Journal of Dermatological Case Reports, 2016, 10, 35-38.	1.1	14
28	BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients. British Journal of Dermatology, 2017, 177, e94-e95.	1.5	11
29	Incidence of Auto-Immune Pemphigus in the Midi-Pyrénées Region in 2002–2006. Dermatology, 2010, 22 97-102.	20, _{2.1}	10
30	Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma. European Journal of Cancer, 2018, 93, 147-149.	2.8	10
31	Advanced Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients. Dermatology, 2019, 235, 516-521.	2.1	7
32	A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. Journal of Investigative Dermatology, 2021, 141, 761-769.e2.	0.7	7
33	Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database. ESMO Open, 2021, 6, 100284.	4.5	7
34	Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis. JMIR Cancer, 2022, 8, e35930.	2.4	7
35	Physicians involved in the care of patients with high risk of skin cancer should be trained regarding sun protection measures: evidence from a cross sectional study. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 19-23.	2.4	6
36	Characterization and Outcomes of Disease Progression in 52 Patients Treated with <i>BRAF</i> -V600 + MEK Inhibitors for Advanced Melanoma. Dermatology, 2018, 234, 92-98.	2.1	5

NICOLAS MEYER

#	Article	IF	CITATIONS
37	Survival estimation of melanoma patients with brain metastasis using the Melanoma-molGPA score: external validation from a French cohort. Melanoma Research, 2020, 30, 472-476.	1.2	5
38	Combining TNF blockade with immune checkpoint inhibitors in patients with cancer. Nature Reviews Rheumatology, 2021, 17, 577-577.	8.0	4
39	PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma. Melanoma Research, 2020, 30, 580-589.	1.2	4
40	Aggressive locoregional behavior of cutaneous squamous cell carcinoma during ruxolitinib use. Annales De Dermatologie Et De Venereologie, 2021, 148, 140-141.	1.0	3
41	A case of merkel leptomeningeal evolution after complete remission upon anti–PD-1 treatment. European Journal of Cancer, 2019, 113, 55-57.	2.8	2
42	Management of Autoimmune Bullous Diseases in France: A Nationwide Network of 30 Centers. Dermatologic Clinics, 2011, 29, 659-662.	1.7	1